ritlecitinib tosylate · Pfizer · NDA 215830
Litfulo
Earliest generic entry, as listed
17 Oct 2041
Blocked by patent: US 12116368.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12116368 | drug substance · sets the listed date | 17 Oct 2041 |
| US 12077533 | use U-3994 | 3 Dec 2034 |
| US 9617258 | drug substance, drug product | 3 Dec 2034 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 23 Jun 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215830 · 001 · RLD | capsule, oral | EQ 50MG BASE | 17 Oct 2041 |